Skip to main content
Supplement ScienceSupplementScience

Benefits of Palmitoylethanolamide (PEA)

Evidence:Moderate
·

This content is for informational purposes only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary — consult your healthcare provider before starting any supplement. Full disclaimer

Evidence-Based Benefits

  • Chronic pain reduction — a 2017 meta-analysis (Paladini et al., 12 RCTs, n=1,188) found PEA significantly reduced pain intensity compared to placebo or standard therapy across multiple chronic pain conditions
  • Neuropathic pain — Hesselink and Hekker (2012) reviewed multiple trials showing PEA 600-1,200mg daily reduced sciatic, diabetic neuropathy, and carpal tunnel pain by 40-60%
  • PPAR-alpha activation — PEA is a direct agonist of peroxisome proliferator-activated receptor alpha, which suppresses NF-kB and reduces pro-inflammatory gene expression
  • Mast cell stabilization — PEA reduces mast cell degranulation and histamine release via the ALIA mechanism (Autacoid Local Inflammation Antagonism), reducing neurogenic inflammation
  • Entourage effect — PEA enhances the activity of endocannabinoid anandamide by inhibiting its degradation enzyme FAAH, amplifying the body's natural pain-modulating system

What the Research Says

Palmitoylethanolamide (PEA), identified in the 1950s, has been extensively studied for its analgesic properties. A comprehensive meta-analysis by Paladini et al. (2016) involving 12 randomized controlled trials (RCTs) with 603 participants demonstrated that PEA significantly reduces chronic pain intensity by 1.04 points every two weeks compared to control. This finding was supported by Schweiger et al. (2024), who conducted a systematic review and meta-analysis of nine studies (742 patients) and found that extended treatment with micron-size PEA for 60 days significantly reduced chronic pain compared to 30 days of treatment (1.36 points, p < 0.01).

PEA's mechanisms include activation of peroxisome proliferator-activated receptor alpha (PPAR-alpha), which reduces inflammation by inhibiting NF-kB signaling, and stabilization of mast cells via the ALIA mechanism. Unlike cannabinoids, PEA does not bind to CB1 or CB2 receptors, avoiding psychoactive effects. It also enhances anandamide signaling indirectly by inhibiting fatty acid amide hydrolase (FAAH).

Micronized forms of PEA improve bioavailability and efficacy. A systematic review by Bortoletto et al. (2025) of 47 RCTs involving 48 studies highlighted that PEA supplementation improves pain management and general well-being with good tolerability in patient populations.

Recent studies further validate PEA's safety and efficacy. Rao et al. (2025) conducted a randomized, double-blind, placebo-controlled crossover trial (n=18) and found that 300 mg of PEA significantly reduced acute menstrual pain scores compared to placebo at multiple time points. Additionally, Cornali et al. (2025) reported in a pilot study (n=19) that a food supplement containing co-micronized PEA-rutin and hydroxytyrosol significantly reduced body weight, BMI, fat mass, and inflammation biomarkers in metabolic syndrome patients compared to placebo.

Overall, PEA's remarkable safety profile—characterized by its lack of psychoactive effects and good tolerability—makes it a promising option for pain management and other health applications.

Related Conditions

Chronic PainNeuropathyInflammation
Full Palmitoylethanolamide (PEA) Guide

References

  1. Meta-analysisPaladini A, Fusco M, Cenacchi T, et al. (2016). Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician. PubMed
  2. ObservationalHesselink JM, Hekker TA (2012). Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. Journal of Pain Research. DOI PubMed
  3. ReviewPetrosino S, Di Marzo V (2017). The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. British Journal of Pharmacology. DOI PubMed
  4. Meta-analysisSchweiger V, Schievano C, Martini A, Polati L, et al. (2024). Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis.. Nutrients. DOI PubMed
  5. Rao A, Erickson J, Briskey D (2025). Palmitoylethanolamide (Levagen+) for acute menstrual pain: a randomized, crossover, double-blind, placebo-controlled trial.. Women & health. DOI PubMed
  6. Meta-analysisBortoletto R, Comacchio C, Garzitto M, Piscitelli F, et al. (2025). Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations.. Brain, behavior, & immunity - health. DOI PubMed
  7. Cornali K, Di Lauro M, Marrone G, Masci C, et al. (2025). The Effects of a Food Supplement, Based on Co-Micronized Palmitoylethanolamide (PEA)-Rutin and Hydroxytyrosol, in Metabolic Syndrome Patients: Preliminary Results.. Nutrients. DOI PubMed
Show 5 more references
  1. Invernizzi M, Mulè S, Lippi L, Galla R, et al. (2025). Evaluation of the Clinical Efficacy of a Novel Palmitoylethanolamide-Equisetum arvense Supplement for the Management of Chronic Pain: Findings from a Prospective Clinical Trial.. Medical sciences (Basel, Switzerland). DOI PubMed
  2. Cominacini M, Valenti MT, Braggio M, Caramori A, et al. (2025). Unlocking Relief: Investigating the Impact of a Fixed Combination of Acetyl-L-Carnitine and Palmitoylethanolamide on Traumatic Acute Low Back Pain.. European journal of neurology. DOI PubMed
  3. Piccolo V, Marzocchi A, Maisto M, Summa V, et al. (2025). Fixed combination of palmitoylethanolamide and melatonin in preventive therapy of migraine: results from a randomized clinical trial.. Frontiers in nutrition. DOI PubMed
  4. Didangelos T, Karlafti E, Kotzakioulafi E, Giannoulaki P, et al. (2024). Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy.. Nutrients. DOI PubMed
  5. Rhodes CH, Hong BV, Tang X, Weng CY, et al. (2024). Absorption, anti-inflammatory, antioxidant, and cardioprotective impacts of a novel fasting mimetic containing spermidine, nicotinamide, palmitoylethanolamide, and oleoylethanolamide: A pilot dose-escalation study in healthy young adult men.. Nutrition research (New York, N.Y.). DOI PubMed